Arbitration Claim Filed Against U.S. Subsidiary
First written in FY2020-Q2. 3 of 9 entries say "Materialised", first in FY2020-Q2. Latest entry: FY2022-Q2.
Linical moved to the "Worse" side of this theme in 2019, 5 years before the typical company in this theme (2024).
20 other companies' latest entry also says "Mitigated".
- FY2022-Q2MitigatedAnnual report
「As a result, the dispute was resolved, and no further related expenses will be incurred.」
A settlement agreement was concluded regarding the arbitration and dispute concerning clinical trials undertaken by ACV before its acquisition, bringing the dispute to a conclusion and eliminating related costs going forward, according to the disclosure. - FY2022-Q1RestatedAnnual report
「Arbitration-related costs ¥45,321 thousand ¥46,152 thousand」
The arbitration proceedings concerning clinical trials previously undertaken by ACV, the predecessor of the U.S. subsidiary, continued, and arbitration-related costs of ¥46,152 thousand were recognized. Although this was an increase from ¥45,321 thousand in the same period of the previous year, no material change in the ongoing arbitration proceedings was disclosed. - FY2021WorsenedAnnual report
「Arbitration-related costs ¥198,701 thousand Settlement payment ¥133,166 thousand」
For the full year, costs related to the arbitration and acquisition price adjustment concerning clinical trials previously undertaken by ACV amounted to ¥198,701 thousand, and a settlement payment of ¥133,166 thousand related to transactions with a customer was also recognized as an extraordinary loss. - FY2021-Q3Increase in arbitration-related costs and customer settlement paymentAnnual report
「Profit attributable to owners of the parent was ¥157 million, down 60.6% year on year, as legal fees and other costs related to arbitration concerning matters undertaken before the acquisition by Accelovance, Inc., the predecessor of Linical Accelovance America, Inc. (LAA), and negotiations with LAA's seller, as well as a settlement payment to a customer, were incurred, despite tax refunds and other benefits arising in the United States.」
Costs related to the arbitration concerning clinical trials previously undertaken by ACV and the acquisition price adjustment continued, and a settlement payment to a customer was also incurred during the current period. - FY2021-Q2RestatedAnnual report
「Arbitration-related costs ¥55,061 thousand ¥60,171 thousand」
Costs related to the arbitration concerning a clinical trial previously undertaken by ACV and the acquisition price adjustment continued, and arbitration-related costs increased from ¥55,061 thousand in the same period of the previous year to ¥60,171 thousand. - FY2021-Q1RestatedAnnual report
「Regarding clinical trial work undertaken by Accelovance, Inc. (referred to below as ACV), the predecessor of our subsidiary Linical Accelovance America, Inc., on behalf of Topical Remedy, LLC (referred to below as TR), an arbitration claim seeking payment of more than $12,000,000 was filed with the AMERICAN ARBITRATION ASSOCIATION on 11 June 2019. TR paid the costs required to commence the arbitration proceedings on 15 October 2019, and the proceedings consequently began.」
The arbitration proceedings seeking payment of more than $12 million concerning a clinical trial previously undertaken by ACV continued, and arbitration-related costs of ¥45,321 thousand were recognized as an extraordinary loss in the first quarter. - FY2020MaterialisedAnnual report
「These were legal fees and other costs incurred in connection with the arbitration.」
The arbitration concerning a clinical trial previously undertaken by ACV continued, and arbitration-related costs of ¥70,811 thousand were recognized as an extraordinary loss. - FY2020-Q3MaterialisedAnnual report
「These were legal fees and other costs incurred in connection with the arbitration.」
The arbitration proceedings concerning ACV, the predecessor of the U.S. subsidiary, continued, and legal fees and other costs of ¥55,407 thousand related to the arbitration were recognized as an extraordinary loss. - FY2020-Q2MaterialisedAnnual report
「Regarding clinical trial work undertaken by Accelovance, Inc. (referred to below as ACV), the predecessor of our subsidiary Linical Accelovance America, Inc., on behalf of Topical Remedy, LLC (referred to below as TR), an arbitration claim seeking payment of more than $12,000,000 was filed with the AMERICAN ARBITRATION ASSOCIATION on 11 June 2019. TR paid the costs required to commence the arbitration proceedings on 15 October 2019, and the proceedings consequently began.」
An arbitration claim seeking payment of more than $12 million was filed regarding a clinical trial previously undertaken by ACV, the predecessor of LAA, and the arbitration proceedings began. Legal fees and other costs of ¥55,061 thousand related to the arbitration were recognized as an extraordinary loss.